代谢组学在中医药诊疗冠心病研究中的应用进展  

Application progress of metabonomics in diagnosis and treatment of coronary heart disease by traditional Chinese medicine

作　　者：仲东生 姚魁武[1,3] 李娜 林建国[1] 段锦龙 王擎擎 李成 孙晓宁 张笑霄 谭猛 ZHONG Dongsheng;YAO Kuiwu;LI Na;LIN Jianguo;DUAN Jinlong;WANG Qingqing;Li Cheng;SUN Xiaoning;ZHANG Xiaoxiao;TAN Meng(Guanganmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China;Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China;Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]中国中医科学院广安门医院,北京100053 [2]贵州中医药大学,贵阳550025 [3]中国中医科学院眼科医院,北京100040 [4]北京中医药大学,北京100029

出　　处：《中华中医药杂志》2024年第7期3597-3602,共6页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：中国中医科学院科技创新工程重大攻关项目(No.CI2021A00906);国家自然科学基金项目(No.81873173);国家重点研发计划(No.2019YFC1708703)。

摘　　要：随着代谢组学的发展,依靠高通量和高灵敏度代谢分析平台,可以定性或定量分析冠心病患者体内的内源性小分子代谢产物,并找到特定的生物标志物,以便于早期诊断和干预。文章通过检索PubMed、中国知网(CNKI)数据库近年来基于代谢组学在冠心病早期诊断、生物标志物的发现、中医证候的鉴别以及中医药在冠心病治疗方面的应用研究进展进行综述,以期为中医药诊疗冠心病提供依据。With the development of metabolomics,relying on high-throughput and high-sensitivity metabolic analysis platforms,it is possible to qualitatively or quantitatively analyze endogenous small molecule metabolites in patients with coronary heart disease(CHD)and find specific biomarkers for early diagnosis and intervention.The paper review the research progress based on metabolomics in early diagnosis of CHD,discovery of biomarkers,identification of traditional Chinese medicine(TCM)evidence,and application of TCM in the treatment of CHD in recent years by searching PubMed and CNKI databases,in order to provide a basis for the diagnosis and treatment of CHD by TCM.

关 键 词：代谢组学 冠心病 中医证候 代谢途径 生物标志物 诊断 治疗 进展 

分 类 号：R259[医药卫生—中西医结合]